LIMNW
Liminatus Pharma, Inc. Warrants
NASDAQ · Healthcare · Biotechnology · US
$0.06
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 986.00 | — | — | — | — |
| Gross Profit | (986.00) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 1.0M | — | 2.7M | 3.8M | 1.9M |
| SG&A Expense | 3.1M | 3.0M | 645.0K | 1.1M | 856.0K |
| General & Admin Expense | 3.1M | 3.0M | 645.0K | 1.1M | 856.0K |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (423.7K) | (2.2M) | — |
| Total Operating Expenses | 4.1M | 3.0M | 2.9M | 2.6M | 2.7M |
| Cost and Expenses | 4.1M | 3.0M | 2.9M | 2.6M | 2.7M |
| Operating Income (EBIT) | (4.1M) | (3.0M) | (2.9M) | (2.6M) | (2.7M) |
| Non-Operating | |||||
| Interest Income | 8.2K | 76.6K | 137.7K | 10.0K | — |
| Interest Expense | 75.6K | 215.9K | 138.1K | 175.0K | 219.0K |
| Net Interest Income | (67.4K) | (139.3K) | (385.00) | (165.0K) | (219.0K) |
| Other Non-Op Income/Expense | (8.5M) | (7.2M) | 20.9K | 1.4M | (219.0K) |
| Non-Operating Income (excl Interest) | 8.4M | 7.0M | (159.0K) | (1.5M) | — |
| EBT (Pre-Tax Income) | (12.5M) | (10.2M) | (2.9M) | (1.2M) | (2.9M) |
| Income Tax Expense | — | — | 18.8K | 34.0K | — |
| Bottom Line | |||||
| Net Income | (12.5M) | (10.2M) | (2.9M) | (1.2M) | (2.9M) |
| Earnings from Cont. Ops | (12.5M) | (10.2M) | (2.9M) | (1.2M) | (2.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.5M) | (10.2M) | (2.9M) | (1.2M) | (2.9M) |
| Per Share | |||||
| Basic EPS | ($23.70) | ($21.50) | ($20.00) | ($7.50) | ($4.12) |
| Diluted EPS | ($23.70) | ($21.50) | ($20.00) | ($7.50) | ($4.12) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 475071 | 475071 | 143832 | 160251 | 688565 |
| Diluted Shares Outstanding | 475071 | 475071 | 143832 | 160251 | 688565 |
| Profitability Metrics | |||||
| EBITDA | (12.4M) | (10.0M) | (2.7M) | (1.1M) | (2.7M) |
| D&A | 1.6K | 1.8K | — | — | 1.0K |
| EBIT | (12.4M) | (10.0M) | (2.7M) | (1.1M) | (2.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026